China Aoxing Pharmaceutical Company Announces Successful Completion Of Phase III Registration Clinical Study Of Tilidine For Moderate To Severe Pain
China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG) ("China Aoxing"), a pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced that it completed Phase III clinical study for Tilidine tablets, a novel drug in China to treat acute and chronic moderate to severe pain, including post-operative and cancer pain in adult patients. The drug is designated as a Class III New Medicine with approximately at least four-year market exclusivity protection upon marketing clearance by the China SFDA. "Reaching this pivotal milestone is an important event for the development of our Tilidine franchise, and will enable a complete analysis of the trial results and a timely submission of new drug application (NDA) to the China SFDA. We believe that Tilidine has the potential to become a major player in the underserved pain market in China, " said Mr. Zhenjiang Yue, CEO and Chairman of China Aoxing. "Also, we are looking forward to reporting the top-line results in the coming weeks.
A simple yet enormously effective patient surveillance system implemented by anesthesiologists at Dartmouth-Hitchcock Medical Center (DHMC) in Lebanon, New Hampshire has proven to dramatically decrease the number of rescue calls and intensive care unit transfers in postsurgical patients, allowing doctors to intervene in more cases before a crisis situation develops. Andreas H. Taenzer, M.D., F.A.A.P. and his colleagues published the results of their study in the February 2010 issue of Anesthesiology. The group's study is the first published report of such a surveillance monitoring system, which seeks to detect patient adverse events occurring in the general postoperative care setting when medical staff is immediately available to intervene, but is unaware of the deteriorating condition. "Our primary finding is that early detection of patient deterioration in important areas such as oxygen saturation and heart rate led to fewer rescue events and a decreased need to escalate care, " said Dr.
Environmental Cues Lead to Breast Cancer A group led by Dr. Peter Lloyd Jones at the University of Dundee, Dundee, Scotland; the University of Colorado Denver, Aurora, CO; and the University of Pennsylvania, Philadelphia, PA has demonstrated that tenascin-C affects proto-oncogene function in breast cancer. Their report can be found in the February 2010 issue of The American Journal of Pathology. Breast cancer causes over half a million deaths annually worldwide. Much research has focused on the role of cancer-causing oncogenes and their precursors, non-carcinogenic proto-oncogenes, within the breast epithelium, the tissue from which most breast cancers are derived. The role of the surrounding cells, or stroma, and the molecules they secrete, such as the extracellular matrix, on transformation of proto-oncogenes to oncogenes in breast cancer remains relatively unexplored. To determine how stromal extracellular matrix remodeling affects proto-oncogene expression in breast epithelia, Taraseviciute et al developed a computational model to quantify changes in a 3-D culture of human mammary epithelial cells.
Research performed by a scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has shown that controlled breathing at a slowed rate can significantly reduce feelings of pain. Chronic pain sufferers, specifically fibromyalgia (FM) patients, also reported less pain while breathing slowly, unless they were overwhelmed by negative feelings, sadness or depression. The research was led by Arthur (Bud) Craig, PhD, at Barrow, and was done in collaboration with investigators in the Department of Psychology at Arizona State University. It was published recently in PAIN, the refereed journal of the International Association for the Study of Pain (IASP). The findings offer an explanation for prior reports that mindful Zen meditation has beneficial effects on pain and that yogic breathing exercises can reduce feelings of depression. These results also underline the role that a person's positive or negative attitude can have on their feelings of pain. The study involved two groups of women aged 45 to 65.
A leading clinical research center in Salt Lake City has joined an international trial program to test an experimental new drug designed to treat painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States. Although not life threatening, dysmenorrhea can be debilitating and psychologically taxing and is one of the leading causes of absenteeism from work and school. Current therapies for the condition (including NSAIDs and 'off label' oral contraceptives) are not completely effective for all women and sometimes do not provide satisfactory relief of symptoms, particularly in women with more severe pain. The investigational new drug, presently named VA111913, is designed to tackle the cause of the cramps that can leave some women bedridden, rather than just the symptoms. The Jean Brown Research center is recruiting women of childbearing age who suffer from dysmenorrhea and normally take medicines to treat their menstrual cramps to take part in a clinical research trial.
St. Jude Medical, Inc. (NYSE:STJ) announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the Genesis(TM) spinal cord stimulation system for the management of chronic pain. Spinal cord stimulators are small implanted devices that are used for managing chronic pain of the back, arms and legs, including pain associated with back surgeries that have failed. Spinal cord stimulators - also known as neurostimulators -- deliver mild electrical pulses to leads placed in the epidural space to interrupt or mask the transmission of pain signals to the brain. "The launch of the Genesis system in Japan is a significant step in our continued international growth, " said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to introduce our technology in Japan and to be able to provide a new option for physicians and patients that will help them manage the severest forms of chronic pain." The Genesis neurostimulator features: - Compact size (28 cc) which provides physicians flexibility in placement options - Constant current stimulation for consistent delivery of therapy - Maximum power output of 25.
Christopher J. Wehking, CMP has been hired as the new Director of Meetings and Exhibits at the American Society of Anesthesiologists. Wehking will join the ASA January 25. Wehking currently serves as Director of Meetings and Exhibits for the American Society of Plastic Surgeons (ASPS). During his four years at ASPS, Wehking successfully introduced a new Annual Meeting and Exhibit Program, solidifying the event as the premier educational and exhibit event for the plastic surgery specialty. "Christopher brings to ASA a diverse set of association experiences, knowledge of best practices, and a proven leadership track record will help expand ASA's already-growing Annual Meeting" said ASA Executive Vice-President John Thorner, J.D., CAE. "His experience with the Society of Plastic Surgeons coupled with the experience of other new ASA Directors who have come from other medical societies will help, ASA synthesize the best of the best practices for better serving ASA's 43, 000 members.
DURECT Corporation (Nasdaq: DRRX) announced that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR™ (SABER™ -Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures. We expect to enroll approximately 300 patients at approximately 20 clinical trial sites in the study. "Initiation of our Phase III BESST program represents a significant milestone for DURECT, " stated James E. Brown, President and CEO of DURECT Corporation. "We believe that POSIDUR, if approved, could improve the treatment of patients' post-surgical pain and reduce the use of opioids in this setting." "BESST was designed based on feedback from the FDA as well as input from expert consultants and key opinion leaders, " stated Joe Stauffer, Chief Medical Officer of DURECT Corporation.
A simple technique called mirror therapy seems effective in preventing phantom limb pain in patients undergoing amputation of an arm or leg, suggests a study in the February 2010 issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS). Dr. Steven R. Hanling and colleagues of Naval Medical Center, San Diego, describe the successful use of mirror therapy to prevent phantom pains in soldiers with severe leg injuries requiring amputation. "Although it may sound like 'hocus pocus, ' this is one of many recent reports about the use of mirror therapy in veterans with injured limbs, " comments Dr. Steven L. Shafer of Columbia University, Editor-in-Chief of Anesthesia & Analgesia. Mirror Exercises Let Brain Control, See and React to Healthy Limb Phantom limb pains are a common and difficult problem after amputations-even though the injured limb is removed, the pain continues. "The pain pathways in the spinal cord and brain 'remember' the painful injury, " says Dr.
On behalf of the US Department of Veterans Affairs (VA), Document Storage Systems (DSS) has completed the certification process of GE's Centricity® Perioperative Anesthesia solution, making it the industry's first to be certified under the new process. Certification indicates the solution is fully capable of integration and compatibility with the VA's clinical information system, VistA. The VA serves the country's estimated 23.4 million United States veterans of the armed services. It operates 153 hospitals and 768 outpatient centers across the US and in Puerto Rico. Recently recognized as the top anesthesia information management solution in the industry analyst KLAS1 special report "The Growing Market for Anesthesia Software: Liability, Integration and the Benefits of Adoption" (11/13/09), Centricity Perioperative Anesthesia is part of the electronic health record that helps anesthesia care providers improve patient care while documenting their perioperative experience. The solution provides customizable scripts, which offer supporting information on anesthesia care steps during the surgery-all operated by a simple touch screen interface for optimal speed and error reduction.